Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy

Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01486498

Acronym

SABAL

Enrollment

571

Registered

2011-12-06

Start date

2005-11-30

Completion date

2011-11-30

Last updated

2011-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Effects of Immunotherapy, Hypersensitivity, Quality of Life, Rhino-Conjunctivitis

Brief summary

Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adults (\> 16 years) and allergic to grass pollen and/or house dust mites.

Exclusion criteria

* Allergic patients who had been immunotherapy treated before.

Outcome results